HOME >> BIOLOGY >> NEWS
Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology

Long-term data on Dendreons Mylovenge vaccine presented at American Society of Hematology Meeting

Results of Phase II studies indicate disease stabilization in patients with multiple myeloma, amyloidosis

San Francisco, CA (Dec. 2, 2000) Dendreon Corporation today announced that long-term follow-up data from Phase II trials of its therapeutic vaccine Mylovenge were presented at the American Society of Hematology Annual Meeting in San Francisco. The trials, involving patients with multiple myeloma and with amyloidosis, indicate that Mylovenge causes regression or stabilization in more than 30 percent of patients. In some patients, these benefits were found to extend more than 18 months following treatment.

Data were presented Saturday at the American Society of Hematology Annual Meeting in San Francisco by Dr. Martha Lacy of the Mayo Clinic, principal investigator of studies involving multiple myeloma and amyloidosis patients by and Dr. Malcolm MacKenzie, director of the Sacramento Medical Foundation Blood Center and principal investigator of a multi-center trial involving further patients with multiple myeloma.

In MacKenzies multicenter trial, approximately 40 percent of the 42 multiple myeloma patients evaluated have shown benefits either in terms of disease stabilization or in tumor regression. This includes six patients with decreases in serum M protein and 10 patients with disease stabilization more than six months. Four patients have been stable for more than 18 months following treatment.

In the Mayo trial of multiple myeloma patients, 17 patients were treated with Mylovenge. Clinical responses were seen in five patients, including complete or near-complete regressions. Many of these responses continued for more than one year.

In a further Mayo trial, 10 patients with amyloidosis were treated with Mylovenge. Seven had disease stabilization or regression lasting in four cases for 18 mo
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
1-Dec-2000


Page: 1 2

Related biology news :

1. Long-term effects of carbon monoxide poisoning are an autoimmune reaction
2. Long-term heart damage may result from constant confrontation and defeat
3. Long-term effects of embryo culture on behavior studied
4. Long-term natural gas supplies should meet growing demand in coming decades, study finds
5. Long-term decline of coral reef ecosystems reported
6. Long-term study of humans and deforestation in Amazon Basin gets new support
7. Long-term studies show most intersex adults happy with gender assignments at birth
8. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
9. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
10. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
11. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test ... 16 minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the detection ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , ... in 2020, despite many obstacles created as a result of COVID-19. As a ... its partnered medical practices and medical manufacturers by expanding access to device offerings, ...
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic ... drug treatment. In an effort to better understand the cellular responses to COVID-19, ... imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules ...
(Date:6/28/2020)... ... June 26, 2020 , ... The ... providers, today announced its strong opposition to the recently introduced bicameral Facial ... blanket ban on most federal use of nearly all biometric and related image ...
Breaking Biology Technology:
Cached News: